Todd S. Thomson Sells 18,750 Shares of Actuate Therapeutics (NASDAQ:ACTU) Stock

Actuate Therapeutics (NASDAQ:ACTU) insider Todd S. Thomson sold 18,750 shares of the firm’s stock in a transaction on Wednesday, August 14th. The shares were sold at an average price of $8.00, for a total value of $150,000.00. Following the completion of the sale, the insider now owns 1,184,795 shares in the company, valued at $9,478,360. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Actuate Therapeutics Stock Down 2.2 %

ACTU stock opened at $8.70 on Monday. Actuate Therapeutics has a fifty-two week low of $7.33 and a fifty-two week high of $10.16.

About Actuate Therapeutics

We are a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). We are developing elraglusib (formerly 9-ING-41), an ATP competitive small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3ß, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.